Trial · NCT03157089
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 13 of 13
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | Afatinib 40 mg + Pembrolizumab 200 mg | 16.7 | Percentage of Participants | ||
| Objective Response Rate (ORR) | Afatinib 30 mg + Pembrolizumab 200 mg | 8.3 | Percentage of Participants | ||
| Recommended Phase II Dose (RP2D) | Afatinib + Pembrolizumab | NA | Milligramm (mg) | ||
| Disease Control Rate (DCR) | Afatinib 40 mg + Pembrolizumab 200 mg | 50 | Percentage of participants | ||
| Disease Control Rate (DCR) | Afatinib 30 mg + Pembrolizumab 200 mg | 58.3 | Percentage of participants | ||
| Duration of Objective Response (DOR) | Afatinib 40 mg + Pembrolizumab 200 mg | 2 | Participants | ||
| Duration of Objective Response (DOR) | Afatinib 30 mg + Pembrolizumab 200 mg | 1 | Participants | ||
| Progression-free Survival (PFS) | Afatinib 40 mg + Pembrolizumab 200 mg | 9.0 | 95% Confidence Interval 4.6 to 27.1 | weeks | |
| Progression-free Survival (PFS) | Afatinib 30 mg + Pembrolizumab 200 mg | 14.4 | 95% Confidence Interval 5.0 to 26.1 | weeks | |
| Overall Survival (OS) | Afatinib 40 mg + Pembrolizumab 200 mg | 37.9 | 95% Confidence Interval 15.0 to 59.3 | weeks | |
| Overall Survival (OS) | Afatinib 30 mg + Pembrolizumab 200 mg | 26.6 | 95% Confidence Interval 8.6 to 53.6 | weeks | |
| Tumour Shrinkage | Afatinib 40 mg + Pembrolizumab 200 mg | -7.7 | Standard Deviation 29.83 | Percentage change | |
| Tumour Shrinkage | Afatinib 30 mg + Pembrolizumab 200 mg | 22.0 | Standard Deviation 71.84 | Percentage change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03157089/results